WORLD HEALTH ORGANIZATION
ORGANISATION MONDIALE DE LA SANTÉ
WELTGESUNDHEITSORGANISATION Date: 02 October 2019
ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONAL OFFICE FOR EUROPE Ms Elen Ohov
BUREAU RÉGIONAL DE L’EUROPE
REGIONALBÜRO FÜR EUROPA
Adviser
ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО European Union Affairs and International Co-
Head office:
operation Department
UN City, Marmorvej 51, Ministry of Social Affairs
DK-2100 Copenhagen Ø, Denmark Suur-Ameerika 1
Tel.: +45 45 33 70 00; Fax: +45 45 33 70 01
Email:
[email protected] 10122 Tallinn
Website: http://www.euro.who.int Estonia
Our reference: Your reference:
Notre référence: Votre référence:
Unser Zeichen: Ihr Zeichen:
См. наш номер: На Ваш номер:
Dear Ms Ohov,
WHO European Conference on Screening
UN City, Copenhagen, Denmark, 11–12 February 2020
I have the honour to inform you that the WHO Regional Office for Europe will hold a conference on
screening in Copenhagen, Denmark, on 11–12 February 2020, with the financial support of the German
Government.
The Conference is organized in the framework of a WHO European initiative aimed at improving
decision-making related to screening practices to maximize benefits and minimize harms. It is a
progressive effort to include all Member States of the WHO European Region following the 2019 WHO
European Technical Consultation on Screening. The Conference will include experts, technical advisers
and policy makers in the Region, and will be supported by a WHO Secretariat team from the global,
regional and country levels.
The Conference aims to discuss the harms and benefits of screening for noncommunicable diseases and
other conditions across the life-course, in light of scientific evidence and country experiences. With
supporting policy briefs, guidance documents, expert presentations and country experience, participants
will exchange views on the most pressing challenges and cross-cutting issues regarding screening, such as
legal, ethical and resource implications, as well as political, social, commercial and technological drivers
of screening.
I have the pleasure to invite you to nominate two participants from your country with technical
background and experience in screening, who will be able to share your country experience in relation
screening for noncommunicable diseases and through the life-course. The working languages will be
English and Russian with simultaneous interpretation provided.
Travel for participants will not be covered. This office can offer to arrange and pay for accommodation
and a daily subsistence allowance for the duration of the meeting in accordance with our travel regulations
if required.
UN City, Marmorvej 51 Tel.: +45 45 33 70 00 Email:
[email protected]
DK-2100 Copenhagen Ø Fax: +45 45 33 70 01 Website: http://www.euro.who.int
Denmark
I look forward to receiving your nominations, with the name, functional title and address (including email)
of the proposed participants. We will then communicate directly with the nominees. We would appreciate
if you could reply directly to the Secretariat, NCD Integrated Prevention and Control of
Noncommunicable diseases, email
[email protected] at your earliest convenience, but no later than
8 November 2019, in order to plan adequate time for travel arrangements and related logistics.
Dr Jill Farrington, Coordinator, is responsible for this event, and we would appreciate you addressing
your reply to her.
Sincerely yours,
Dr Bente Mikkelsen
Director,
Division of Noncommunicable Diseases and Promoting Health through the Life-course
Encls:
Provisional agenda
Scope and purpose
Provisional programme
Copy for information to:
Ms Triin Uusberg, Head, European and International Coordination Department, Ministry of Social Affairs,
Suur-Ameerika 1, 10129 Tallinn, Estonia
H.E. Ms Katrin Saarsalu-Layachi, Ambassador Extraordinary and Plenipotentiary, Permanent Representative,
Permanent Mission of the Republic of Estonia to the United Nations Office and other international
organizations in Geneva, Chemin du Petit-Saconnex 28A, CH-1209 Genève, Switzerland
H.E. Mr Märt Volmer, Ambassador Extraordinary and Plenipotentiary, Embassy of the Republic of Estonia,
Frederiksgade 19, 4th floor, 1265 Copenhagen K, Denmark
Ms Marge Reinap, Head of WHO Office, WHO Country Office, Estonia, Paldiski Road 81, 10617 Tallinn,
Estonia
–2–
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
WHO European Conference on Screening /02
UN City, Copenhagen, Denmark 23 September 2019
11–12 February 2020 Original: English
Scope and purpose
While there appears to be a growing trend in the WHO European Region towards more screening
for noncommunicable diseases and health checks throughout the life-course, policy makers,
health professionals and the public often seem unaware of the potential harms of screening, its
cost and burden on the health system and the need for strong quality assurance. This Conference
aims to increase the effectiveness of screening programmes within the Region, maximizing
benefits and minimizing harms.
Screening is defined as the presumptive identification of an unrecognized disease or condition in
an apparently healthy, asymptomatic population by means of tests, examinations or other
procedures that can be applied rapidly and easily to the target population.1 Such a definition
covers a potentially broad range of population ‘checks’, covering a wide variety of conditions
and ages. The primary aim of screening is to improve prognosis of the health condition through
earlier intervention and management with the hope to reduce mortality and suffering from a
disease. Depending on the nature of the health conditions and the modalities of the screening,
however, benefits can vary considerably and in some cases be minimal or even null. Within the
WHO European Region, countries are implementing screening programmes for a wide range of
conditions throughout the life-course even though there is not a clear evidence-base for
effectiveness.
All screening has the potential to do harm2 and these harms - like benefits - depend on the health
conditions considered and the modalities of the screening. For example, screening for prostate
cancer has been shown to bring very limited benefit in terms of reduction of mortality while
harms (notably over-diagnosis and over-treatment) have proven to be important even in the
controlled context of randomized control trials3. On the other side of the spectrum, organized
screening programs for cervical cancer have proven to bring major benefits (decreased incidence
and decreased mortality) with minimal harms when quality is adequately assured4. Assessing the
balance between harms and benefits is not straightforward however and for some conditions it
remains largely unknown, making policy decisions on screening a particularly difficult exercise.
Decision-making regarding screening implementation can be influenced by many cultural,
economic and political factors, which in many occurrences overshadow evidence, even when
those are solid and clear.
1
http://www.who.int/cancer/prevention/diagnosis-screening/screening/en/
2
“All screening programmes do harm, some do good as well…”. See for example: Muir Gray JA, Patnick J, Blanks,
RG. Maximising benefit and minimising harm of screening. BMJ 2008;336:480.
3
Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge
JB, Lin K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann
Intern Med. 2011 Dec 6;155(11):762-71.
4
WHO 2014. Comprehensive cervical cancer control - A guide to essential practice
http://www.who.int/cancer/publications/cervical-cancer-guide/en/
Scope and purpose
page 2
Such practices raise questions regarding the amount of harm done to healthy individuals
throughout the WHO European Region. This amount has not been quantified, nor has there been
an evaluation of the amount of public resources invested in programs that don’t bring benefit,
however both are suspected to be important. The WHO Regional Office for Europe has therefore
undertaken an initiative to explore these issues further with a focus on NCDs and other
conditions throughout the life-course. A WHO European Technical Consultation on Screening
held on 26–27 February 2019 clarified the evidence available for various screening practices
(including harms and benefits), the current screening practices taking place in European
countries and the important divergence between evidence and practice. Publications and
guidance produced as a result of this first consultation will be shared on the occasion of the
present meeting. The 2019 consultation resulted also in identification of some cross-cutting
issues and possible solutions that will be further explored during the present meeting.
The purpose of the present meeting is to generate knowledge and provide tools to improve
screening practices and policy decision-making related to screening. The meeting will take place
over two days and involve a WHO Secretariat team from the global, regional and country levels,
as well as policy makers from Member States, technical experts and WHO Collaborating
Centres. Expert presentations and country experiences will highlight cross-cutting issues (such as
political, social, commercial and technological drivers of screening, legal, ethical and resource
implications of screening, health literacy and the role of civil society) and potential solutions for
adequate decision-making and successful screening. The outcomes of the meeting will be a set of
key messages supporting smart screening strategies and practices.
The working languages of the meeting will be English and Russian with simultaneous
interpretation provided.
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
WHO European Conference on Screening /03
UN City, Copenhagen, Denmark 23 September 2019
11–12 February 2020 Original: English
Provisional agenda
1. Opening session
2. Adoption of agenda and programme
3. Reflection from the 2019 Technical Consultation
4. Good principles of screening
5. Successes and challenges in screening
6. Applying good screening principles in practice
7. Health literacy and the role of civil society
8. Political, social, commercial and technological drivers
9. Scaling up effective and evidence-based screening
10. Legal, ethical and resource implications of screening
11. Closing
Saatja: EURO NCD <
[email protected]>
Saadetud: 03.10.2019 09:47
Adressaat: Elen Ohov <
[email protected]>
Koopia: Triin Uusberg <
[email protected]>; SM Info <
[email protected]>;
<
[email protected]>; <
[email protected]>; REINAP, Marge <
[email protected]>
Teema: EST: Invitation for nominations: WHO European Conference on Screening, UN City,
Copenhagen, Denmark, 11–12 February 2020
Manused: 1_EST Screening Conference invitation.pdf; 02_Scope and Purpose_ENG.pdf; 03_SC
Provisional Agenda_ENG.pdf; 04_SC Provisional Programme_ENG.pdf
Dear Ms Ohov,
Please find attached to this email an invitation to nominate candidates to attend the above
mentioned Conference which will take place 11-12 February, 2020.
We would appreciate to receive nominations no later than 8 November 2019.
Please respond directly to this email, attention Dr Jill Farrington, who is responsible for this
event
Sincerely yours
Secretariat, NCD Integrated Prevention and Control of Noncommunicable diseases
On behalf of
Dr Bente Mikkelsen
Director, Division of Noncommunicable Diseases and Promoting Health through the Life-course
WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTÉ
REGIONAL OFFICE FOR EUROPE BUREAU RÉGIONAL DE L'EUROPE
WELTGESUNDHEITSORGANISATION ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
REGIONALBÜRO FÜR EUROPA ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО
WHO European Conference on Screening /04
UN City, Copenhagen, Denmark 23 September 2019
11–12 February 2020 Original: English
Provisional programme
Tuesday, 11 February 2020
08:00–09:00 Registration
09:00–10:30 Plenary 1: Opening and introduction
Opening
Introduction to the programme and expected outcomes
Reflections on the WHO European Technical Consultation on
Screening Overview of outcomes and events since
What are good principles of screening? Presentation of guide,
policy brief and other publications
10:30–11:00 Coffee break and photo
11:00–12:30 Plenary 2: Successes and challenges in screening
A panel of policymakers from countries share their experience
12:30–13:30 Lunch break
13:30–15:00 Parallel sessions A: Applying good screening principles in
practice
Expertise, experience and examples of implementing organized,
evidence-based screening programmes, with sessions to include
governance, quality assurance, monitoring and evaluation.
15:00–15:30 Coffee break
15:30–17:00 Plenary 3: Health literacy and the role of civil society
Panel of perspectives
17:00–17:15 Closing of Day 1
17:30 Reception
Provisional programme
Page 2
Wednesday, 12 February 2020
09:00–10:30 Feedback from Day 1
Plenary 4: Political, social, commercial and technological
drivers of screening
Presentations and discussion
10:30–11:00 Coffee break
11:00–12:30 Parallel sessions B: Scaling up effective and evidence-based
screening
Evidence and experience in implementing screening programmes in
countries, with topics likely to focus on non-cancer screening
examples in particular
12:30–13:30 Lunch break
13:30–15:00 Plenary 5: Legal, ethical and resource implications of screening
Presentations and discussion
15:00–15:30 Coffee break
15:30–17:00 Plenary 6: Conclusions and next steps
Rapporteur’s report
Facilitated discussion
Conclusions
Closing